Beta-blockade was not associated with altered risk for upper gastrointestinal bleeding (UGIB) in this case-control study.
Why this matters
Results from several small studies have suggested beta-blockers protect against UGIB.
- Comorbidities and medication use were higher among patients vs control patients.
- 484 patients taking beta-blockers experienced UGIB.
- Ever and current beta-blocker use was higher among patients vs control patients (26.9% vs 18.1% and 13.6% vs 9.1%, respectively).
- Crude OR for UGIB among beta-blocker users vs nonusers was 1.70.
- After adjustment for confounders, ever beta-blocker use was not associated with UGIB (OR, 1.10; 95% CI, 1.00-1.21).
- In subgroup analysis, the association with UGIB remained neutral for selective vs nonselective beta-blockers, varying degrees of comorbidity, and recency and dosage of beta-blocker.
- Registry-, population-based, case-control study comparing use of beta-blockers among patients with or without UGIB.
- Patients (n=3571): residents of 1 county admitted to hospital between 1995 and 2006 with UGIB (excluding gastric varices and patients with liver disease).
- Control patients (n=35,582): 10 randomly selected age- and sex-matched people from same registries.
- All cases manually validated.
- Outcome: OR for UGIB among beta-blocker users vs nonusers.
- Funding: None.
Confounding lifestyle factors and over-the-counter medications not accounted for.